The purpose of the study was to delineate the efficacy and toxicity of paclitaxel (Taxol, Bristol
Myers Squibb) in the treatment of drug resistant small-cell lung cancer (SCLC). Patients …

Purpose We performed a randomized phase II trial comparing pemetrexed with pemetrexed
plus carboplatin (PC) in patients experiencing relapse after platinum-based chemotherapy. …

… benefit over placebo in pretreated patients with advanced NSCLC.10 The improved outcome
with EGFR TKIs is mainly confined to never smokers and patients who have tumors that …

… Crizotinib was the first anaplastic lymphoma kinase (ALK) inhibitor to receive US Food
and Drug Administration (FDA) approval for the treatment of advanced ALK-positive non–small-cell …

… relationship between pretreatment SCCL-large cell mor… three patients with SCCL-large cell
morphology at autopsy could be that postmortem autolysis obscures the features of this tumor …

… in patients with advanced non-small cell lung cancer (NSCLC) consistently showed greater
survival benefit of pemetrexed in patients with nonsquamous cell carcinoma … cell carcinoma …

… -cell lung cancer and SCLC models; this agent was also tested in non–small-cell lung cancer
patients in … Disease stabilization could be considered a clinically relevant result in patients …

Background The use of biomarkers for selecting non-small cell lung cancer (NSCLC) patients
for treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) …

… On this basis, we aimed to assess dacomitinib versus best supportive care in a phase 3
setting of an unselected population of heavily pretreated patients with non-small-cell lung cancer…

… In this study, vandetanib showed moderate efficacy in pretreated patients with advanced …
been reported for small molecular inhibitors in pretreated patients with typical oncogene-driven …